Acadia Pharmaceuticals Inc (ACAD) shareholders
Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Julian C. Baker Joint filing with Felix J. Baker (25.40%), Baker Bros. Advisors LP (25.30%) and 1 more | 43,294,373 | 25.40% | 13D (active) amendment | Feb 24, 2026 |
| BlackRock, Inc. | 19,878,746 | 11.90% | 13G (passive) amendment | Jan 31, 2025 |
| Vanguard Portfolio Management | 8,781,007 | 5.15% | 13G (passive) | Mar 31, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (5.20%) | 8,705,501 | 5.20% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACAD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 42,912,904 | 24.91% | $1.09B | +16,214 | 5.44% |
| BlackRock, Inc. | 22,515,173 | 13.07% | $569.63M | +964,252 | 0.01% |
| State Street Corp | 9,076,212 | 5.27% | $229.63M | +743,441 | 0.01% |
| Vanguard Portfolio Management LLC | 8,838,450 | 5.13% | $223.61M | +166,805 | 0.01% |
| Rtw Investments, LP | 7,144,524 | 4.15% | $180.76M | – | 1.54% |
| Vanguard Capital Management LLC | 5,763,750 | 3.35% | $145.82M | +102,350 | 0.00% |
| Dimensional Fund Advisors LP | 3,694,988 | 2.14% | $93.48M | +539,828 | 0.02% |
| Geode Capital Management, LLC | 3,358,129 | 1.95% | $84.98M | −106,560 | 0.00% |
| Palo Alto Investors LP | 2,864,096 | 1.66% | $72.46M | −8,599 | 10.01% |
| Goldman Sachs Group Inc | 2,580,115 | 1.50% | $65.28M | +1,022,311 | 0.01% |
| Qube Research & Technologies Ltd | 2,446,610 | 1.42% | $61.90M | +1,496,311 | 0.06% |
| Point72 Asset Management, L.P. | 2,433,168 | 1.41% | $61.56M | −144,748 | 0.07% |
| Citadel Advisors LLC | 2,182,177 | 1.27% | $55.21M | +1,559,417 | 0.01% |
| Pictet Asset Management Holding SA | 1,983,198 | 1.15% | $50.15M | −42,846 | 0.05% |
| Arrowstreet Capital, Limited Partnership | 1,969,445 | 1.14% | $49.83M | +399,954 | 0.02% |
| Marshall Wace, Llp | 1,764,838 | 1.02% | $44.65M | +1,688,651 | 0.04% |
| D. E. Shaw & Co., Inc. | 1,697,937 | 0.99% | $42.96M | +968,101 | 0.02% |
| Braidwell LP | 1,646,399 | 0.96% | $41.65M | −824,800 | 1.54% |
| Norges Bank | 1,623,308 | 0.94% | $41.07M | New | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,438,198 | 0.83% | $36.39M | – | 0.79% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 352 | 169M | 97.9% | 50 / 134 | 112 / 35 | 17M | 13M |
| Q1 2026 | 343 | 165M | 95.8% | 46 / 114 | 129 / 34 | 28M | 14M |
| Q4 2025 | 336 | 166M | 96.6% | 53 / 121 | 118 / 43 | 16M | 17M |
| Q3 2025 | 334 | 168M | 97.5% | 58 / 126 | 106 / 32 | 20M | 23M |
| Q2 2025 | 311 | 171M | 99.3% | 47 / 102 | 122 / 54 | 15M | 17M |
| Q1 2025 | 320 | 173M | 100.0% | 64 / 101 | 102 / 37 | 30M | 19M |
| Q4 2024 | 296 | 163M | 94.8% | 70 / 108 | 75 / 29 | 23M | 17M |
| Q3 2024 | 258 | 157M | 91.2% | 36 / 90 | 81 / 42 | 26M | 19M |
| Q2 2024 | 266 | 162M | 94.1% | 40 / 108 | 81 / 38 | 19M | 23M |
| Q1 2024 | 268 | 166M | 96.3% | 51 / 104 | 74 / 55 | 18M | 14M |
| Q4 2023 | 276 | 162M | 93.9% | 60 / 105 | 70 / 29 | 15M | 9M |
| Q3 2023 | 248 | 156M | 90.7% | 40 / 94 | 72 / 27 | 14M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
311 funds held ACAD in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACAD | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7,634,753 | 4.43% | $193.16M | 0.17% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,074,465 | 2.36% | $103.08M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,977,187 | 2.31% | $100.62M | 0.94% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,348,997 | 1.94% | $84.73M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,949,287 | 1.71% | $74.62M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,699,377 | 0.99% | $42.99M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,457,420 | 0.85% | $36.87M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,408,238 | 0.82% | $36.43M | 0.11% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,196,003 | 0.69% | $30.26M | 0.33% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,189,901 | 0.69% | $30.10M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 1,166,003 | 0.68% | $29.50M | 0.17% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1,138,699 | 0.66% | $28.81M | 0.35% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 823,219 | 0.48% | $20.83M | 0.82% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 812,021 | 0.47% | $20.54M | 0.18% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 728,230 | 0.42% | $18.42M | 0.35% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer, Director | 14,803 | 0.01% | Mar 26, 2026 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 71,322 | 0.04% | Oct 30, 2026 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 19,044 | 0.01% | Jul 31, 2026 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 13,088 | 0.01% | Jun 29, 2026 |
| Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 11,280 | 0.01% | Mar 26, 2026 |
| Thomas Garner | EVP, Chief Commercial Officer | – | – | Mar 10, 2026 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 62,105 | 0.04% | Nov 19, 2024 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 3,761,611 | 2.18% | Jun 2, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 39,487,463 | 22.92% | Jun 2, 2026 |
| Felix Baker | Director, 10% owner | 38,587,857 | 22.40% | Jun 2, 2026 |
| 667, L.P. | Director, 10% owner | 39,132,562 | 22.71% | Jun 2, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 39,452,627 | 22.90% | Jun 2, 2026 |
| Julian Baker | Director, 10% owner | 39,433,853 | 22.89% | Jun 2, 2026 |
| Jonathan Poole | Director | 2,010 | 0.00% | Jun 1, 2026 |
| James M. Daly | Director | 12,148 | 0.01% | Jun 1, 2026 |
| Edmund Harrigan | Director | 43,148 | 0.03% | Jun 1, 2026 |
| Laura Brege | Director | 23,202 | 0.01% | Jun 1, 2026 |
| Elizabeth A. Garofalo | Director | 33,489 | 0.02% | Jun 1, 2026 |
| Adora Ndu | Director | 32,908 | 0.02% | Jun 1, 2026 |
| Daniel B. Soland | Director | 44,041 | 0.03% | Jun 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Oct 30, 2026 | Sale(10b5-1 plan) | −3,321 | $20.88 | $69.34K | 71,322 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Oct 15, 2026 | Award | +6,815 | – | – | 74,643 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Option exercise | +14,292 | $17.84 | $254.97K | 82,120 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Sale(10b5-1 plan) | −9,292 | $29.34 | $272.63K | 67,828 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Sale(10b5-1 plan) | −5,000 | $29.00 | $145.00K | 77,120 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 5, 2026 | Sale(10b5-1 plan) | −5,849 | $29.00 | $169.62K | 67,828 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 5, 2026 | Option exercise | +5,849 | $17.84 | $104.35K | 73,677 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 30, 2026 | Sale(10b5-1 plan) | −16,508 | $26.13 | $431.35K | 19,044 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 30, 2026 | Sale(10b5-1 plan) | −50 | $26.17 | $1.31K | 18,994 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 29, 2026 | Option exercise | +32,272 | – | – | 35,552 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Jun 26, 2026 | Sale(10b5-1 plan) | −11,421 | $26.08 | $297.86K | 13,088 |
| Brothers Life Sciences LP Baker Director, 10% owner | May 29, 2026 | Award | +18,622 | – | – | 39,384,587 |
| Brothers Life Sciences LP Baker Director, 10% owner | May 29, 2026 | Award | +18,622 | – | – | 3,677,357 |
| Edmund Harrigan Director | May 29, 2026 | Option exercise | +8,107 | – | – | 43,148 |
| Jonathan Poole Director | May 29, 2026 | Option exercise | +2,010 | – | – | 2,010 |
| Adora Ndu Director | May 29, 2026 | Option exercise | +8,107 | – | – | 32,908 |
| Laura Brege Director | May 29, 2026 | Option exercise | +8,107 | – | – | 23,202 |
| Elizabeth A. Garofalo Director | May 29, 2026 | Option exercise | +8,107 | – | – | 33,489 |
| James M. Daly Director | May 29, 2026 | Option exercise | +8,107 | – | – | 12,148 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 26, 2026 | Sale | −5,401 | $21.18 | $114.39K | 24,509 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | May 4, 2026 | Sale(10b5-1 plan) | −3,506 | $21.79 | $76.40K | 66,145 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 4, 2026 | Sale(10b5-1 plan) | −1,332 | $21.79 | $29.02K | 29,129 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | May 1, 2026 | Option exercise | +6,815 | – | – | 69,651 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 1, 2026 | Option exercise | +2,596 | – | – | 30,461 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −1,030 | $22.20 | $22.87K | 27,865 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −2,709 | $22.20 | $60.14K | 62,836 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Apr 5, 2026 | Option exercise | +2,010 | – | – | 28,895 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Apr 5, 2026 | Option exercise | +5,276 | – | – | 65,545 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −37 | $21.72 | $804 | 60,269 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −3,171 | $21.65 | $68.65K | 60,306 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −12 | $21.73 | $261 | 26,885 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −1,097 | $21.65 | $23.75K | 26,897 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 25, 2026 | Sale(10b5-1 plan) | −4,177 | $21.47 | $89.68K | 57,299 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 25, 2026 | Option exercise | +6,178 | – | – | 63,477 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Mar 25, 2026 | Sale(10b5-1 plan) | −3,435 | $21.47 | $73.75K | 3,280 |
| Adams Catherine Owen Chief Executive Officer, Director | Mar 25, 2026 | Sale(10b5-1 plan) | −11,641 | $21.47 | $249.93K | 14,803 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Mar 25, 2026 | Sale(10b5-1 plan) | −3,844 | $21.47 | $82.53K | 11,280 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 25, 2026 | Option exercise | +2,142 | – | – | 27,994 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 25, 2026 | Sale(10b5-1 plan) | −833 | $21.47 | $17.88K | 25,852 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 24, 2026 | Option exercise | +8,138 | – | – | 61,476 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Mar 24, 2026 | Option exercise | +6,715 | – | – | 6,715 |
| Adams Catherine Owen Chief Executive Officer, Director | Mar 24, 2026 | Option exercise | +23,509 | – | – | 26,444 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Mar 24, 2026 | Option exercise | +7,515 | – | – | 15,124 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 24, 2026 | Option exercise | +1,627 | – | – | 26,685 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Feb 9, 2026 | Sale(10b5-1 plan) | −6,950 | $23.38 | $162.49K | 7,609 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Feb 6, 2026 | Option exercise | +12,944 | – | – | 14,559 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 18, 2025 | Sale(10b5-1 plan) | −4,084 | $23.69 | $96.75K | 25,058 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 18, 2025 | Sale(10b5-1 plan) | −10,262 | $23.69 | $243.11K | 53,338 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 17, 2025 | Option exercise | +3,966 | – | – | 25,176 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 17, 2025 | Option exercise | +3,966 | – | – | 29,142 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 17, 2025 | Option exercise | +9,913 | – | – | 63,600 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 17, 2025 | Option exercise | +9,913 | – | – | 53,687 |
| James M. Daly Director | Nov 10, 2025 | Sale | −30,000 | $22.37 | $671.10K | 4,041 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Sep 15, 2025 | Sale(10b5-1 plan) | −3,498 | $23.65 | $82.73K | 43,447 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Sep 12, 2025 | Award | +6,815 | – | – | 46,945 |
| Elizabeth A. Garofalo Director | Sep 2, 2025 | Sale | −1,600 | $25.98 | $41.57K | 25,382 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 18, 2025 | Sale(10b5-1 plan) | −22,000 | $25.18 | $553.96K | 40,130 |
| Laura Brege Director | Jun 4, 2025 | Sale | −14,446 | $21.78 | $314.63K | 15,095 |
| Edmund Harrigan Director | May 29, 2025 | Option exercise | +9,387 | – | – | 35,041 |
| Laura Brege Director | May 29, 2025 | Option exercise | +9,387 | – | – | 29,541 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Acadia Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,765 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark C. Schneyer Officer | Aug 5, 2026 | 5,849 | $158.80K | Aug 5, 2026 | Stock Option Exercise |
| James Kihara Officer | Jun 26, 2026 | 11,421 | $297.00K | Jun 26, 2026 | Compensation |
| James Kihara Officer | May 26, 2026 | 5,401 | $114.39K | May 26, 2026 | Performance Shares |
| James M. Daly Director | Nov 10, 2025 | 30,000 | $670.98K | Nov 10, 2025 | Restricted Stock |
| Mark C. Schneyer Officer | Aug 18, 2025 | 22,000 | $557.26K | Aug 18, 2025 | Compensation |
| Laura Brege Director | Jun 4, 2025 | 14,446 | $314.64K | Jun 4, 2025 | Restricted Stock |
| Mark C. Schneyer Officer | May 16, 2025 | 2,000 | $35.20K | May 16, 2025 | Compensation |
| James Kihara Officer | May 16, 2025 | 4,000 | $70.40K | May 16, 2025 | Compensation |
| Elizabeth A. Garofalo Director | Mar 6, 2025 | 4,919 | $89.67K | Mar 5, 2025 | RESTRICTED STOCK |
| James Kihara Officer | Dec 15, 2023 | 2,000 | $56.12K | Dec 15, 2023 | Restricted Stock Units |
| James Kihara Officer | Sep 15, 2023 | 2,000 | $51.70K | Sep 15, 2023 | Vested RSU shares |
| Mark C. Schneyer Officer | Aug 21, 2023 | 10,000 | $293.30K | Aug 21, 2023 | Vested RSU Shares |
| Stephen Davis Officer, Director | Jul 14, 2023 | 100,000 | $2.58M | Jul 14, 2023 | Stock Option Exercise |
| Stephen Davis Officer, Director | Jul 13, 2023 | 71,602 | $1.77M | Jul 11, 2023 | Vested RSU shares |
| James Kihara Officer | Jun 15, 2023 | 2,000 | $48.28K | Jun 15, 2023 | Vested RSU shares |
Congress trades
1 trade in Acadia Pharmaceuticals reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Jun 16, 2022 | $1K–15K | Jul 28, 2022 |
See a number that looks wrong?